Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies.
esophageal carcinoma
mesothelin expression
targeted therapy
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
12
2018
accepted:
06
03
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Mesothelin is expressed at very low levels by normal mesothelial cells but is overexpressed in several human cancers. This makes mesothelin a promising target for immunotherapy. Limited data exist about mesothelin expression in esophageal carcinoma. In a current clinical trial, the highly potent anti-mesothelin antibody anetumab ravtansine is used in patients with mesothelin-positive tumors. Response rates are correlated with mesothelin expression (using the Ventana antibody) in tumor cells. No data are available on expression levels using the Ventana antibody. Most data have been generated using the Novocastra antibody. As patients are selected for clinical trials based on antibody staining of tumor samples, a comparison of these two available antibodies is crucial. We analyzed 481 esophageal carcinomas [373 esophageal adenocarcinomas (EACs), 108 esophageal squamous cell carcinomas (ESCCs)] using two different monoclonal antibodies (Novocastra and Ventana) for mesothelin expression (low-mid and high-level expression, as used in one clinical trial). We also checked for the correlation of these results with clinical and molecular data. We revealed different staining results for both antibodies in EACs: Ventana: 53.6% (low expression: 25.3%; high expression: 28.3%) and Novocastra: 35.7% (low expression: 21.2%; high expression 14.5%). In ESCC we found comparable staining results: Ventana: 13.3% (low expression: 9.5%; high expression: 3.8%) and Novocastra: 13% (low expression: 11.1%; high expression: 1.9%). ARID1a-deficient EAC patients demonstrated significantly higher rates of mesothelin-positive tumors than ARID1a intact EAC patients. No correlations were found with other molecular alterations ( To the best of our knowledge, this is the largest study analyzing the importance of mesothelin expression in esophageal carcinoma. This study revealed a significant number of mesothelin-positive esophageal carcinomas, especially adenocarcinomas. New therapeutic targets are urgently required to improve the outcome of patients with locally advanced or metastasized esophageal carcinoma. The inhibition of mesothelin can be a new attractive target.
Sections du résumé
BACKGROUND
BACKGROUND
Mesothelin is expressed at very low levels by normal mesothelial cells but is overexpressed in several human cancers. This makes mesothelin a promising target for immunotherapy. Limited data exist about mesothelin expression in esophageal carcinoma. In a current clinical trial, the highly potent anti-mesothelin antibody anetumab ravtansine is used in patients with mesothelin-positive tumors. Response rates are correlated with mesothelin expression (using the Ventana antibody) in tumor cells. No data are available on expression levels using the Ventana antibody. Most data have been generated using the Novocastra antibody. As patients are selected for clinical trials based on antibody staining of tumor samples, a comparison of these two available antibodies is crucial.
METHODS
METHODS
We analyzed 481 esophageal carcinomas [373 esophageal adenocarcinomas (EACs), 108 esophageal squamous cell carcinomas (ESCCs)] using two different monoclonal antibodies (Novocastra and Ventana) for mesothelin expression (low-mid and high-level expression, as used in one clinical trial). We also checked for the correlation of these results with clinical and molecular data.
RESULTS
RESULTS
We revealed different staining results for both antibodies in EACs: Ventana: 53.6% (low expression: 25.3%; high expression: 28.3%) and Novocastra: 35.7% (low expression: 21.2%; high expression 14.5%). In ESCC we found comparable staining results: Ventana: 13.3% (low expression: 9.5%; high expression: 3.8%) and Novocastra: 13% (low expression: 11.1%; high expression: 1.9%). ARID1a-deficient EAC patients demonstrated significantly higher rates of mesothelin-positive tumors than ARID1a intact EAC patients. No correlations were found with other molecular alterations (
CONCLUSION
CONCLUSIONS
To the best of our knowledge, this is the largest study analyzing the importance of mesothelin expression in esophageal carcinoma. This study revealed a significant number of mesothelin-positive esophageal carcinomas, especially adenocarcinomas. New therapeutic targets are urgently required to improve the outcome of patients with locally advanced or metastasized esophageal carcinoma. The inhibition of mesothelin can be a new attractive target.
Identifiants
pubmed: 32547645
doi: 10.1177/1758835920917571
pii: 10.1177_1758835920917571
pmc: PMC7249595
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920917571Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest: The authors declare that there is no conflict of interest.
Références
Am J Gastroenterol. 2008 Nov;103(11):2694-9
pubmed: 18853967
Methods Mol Med. 2005;114:257-68
pubmed: 16156109
Hum Pathol. 2003 Jun;34(6):605-9
pubmed: 12827615
Ann Surg. 2007 Feb;245(2):241-6
pubmed: 17245177
Pathol Res Pract. 2011 Sep 15;207(9):529-37
pubmed: 21944426
Int J Cancer. 1992 Jun 19;51(4):548-54
pubmed: 1351045
Oncoimmunology. 2019 Feb 27;8(5):e1581546
pubmed: 31069143
Am J Surg Pathol. 2003 Nov;27(11):1418-28
pubmed: 14576474
Oncotarget. 2016 Apr 19;7(16):21763-74
pubmed: 26943575
Br J Cancer. 2009 Apr 7;100(7):1144-53
pubmed: 19293794
Eur J Cancer. 2018 May;94:104-114
pubmed: 29550565
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
pubmed: 8552591
Mol Cancer Res. 2008 Feb;6(2):186-93
pubmed: 18245228
Mol Cancer Ther. 2014 Jun;13(6):1537-48
pubmed: 24714131
Oncotarget. 2018 Sep 18;9(73):33844-33852
pubmed: 30333914
J Biol Chem. 2009 Feb 6;284(6):3739-49
pubmed: 19075018
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
Breast Cancer Res Treat. 2012 Jun;133(2):799-804
pubmed: 22418702
J Biol Chem. 2004 Mar 5;279(10):9190-8
pubmed: 14676194
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):482-6
pubmed: 22237988
Clin Cancer Res. 2001 Dec;7(12):3862-8
pubmed: 11751476
Am J Surg Pathol. 2003 Aug;27(8):1031-51
pubmed: 12883236
Ann Surg. 2008 Dec;248(6):902-8
pubmed: 19092334
Nanomedicine. 2008 Dec;4(4):295-301
pubmed: 18691948
Cancer Res. 1992 Jan 1;52(1):181-6
pubmed: 1727378
Int J Cancer. 1992 Feb 1;50(3):373-81
pubmed: 1735605